Bharat Biotech seeks DCGI's nod for phase-3 trial of intranasal Covid vaccine as booster dose

Hyderabad: Bharat Biotech has sought the Drug Controller General of India's (DCGI)  approval to conduct Phase-3 trials of its Covid-19 intranasal vaccine (BBV154) to use as booster dose, as per sources. The sources said Bharat Biotech had filed the application in this regard and was awaiting approval from the Drug Controller General of India. The intranasal vaccine of Covid-19 would be administered to those who have already taken their two vaccine doses. [caption id="" align="aligncenter" width="1200"] Representative image[/caption] Also read | Punjab farmers launch statewide 'rail roko' to press for their pending demands The sources added that an intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and had the potential to prevent transmission. Meanwhile, the Central Drugs Standard Control Organisation approved the extension of Bharat Biotech's COVID-19 vaccine Covaxin's shelf life up to 12 months from the date of manufacture, the vaccine-maker said in a press release. Covaxin is approved for use under the 28-day multi-dose vial policy from Drugs Controller General of India and the WHO Emergency Use Listing (WHO EUL). [caption id="" align="aligncenter" width="770"] Representative image[/caption] Meanwhile, India logged 6,563 new Covid-19 cases, 132 deaths in the last 24 hours, the Ministry of Health and Family Welfare informed on Monday. The active caseload of the country stands at 82,267; the lowest in nearly 1.5 years (572 days). As per the ministry, as many as 8,077 patients recovered from the virus in the last 24 hours, taking the cumulative tally of recovered patients since the beginning of the pandemic to 3,41,87,017. [caption id="" align="aligncenter" width="2119"] Representative image[/caption] “India’s recovery rate stands at 98.39 percent, highest since March 2020,” said the ministry while giving coronavirus update about India. -PTC News

Join Whatsapp Channel